Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GSK $4.2B bet on Merck KGaA bintrafusp alfa goes up in smoke as pharmas cut ties after series of clinical trial flops in lung cancer indications.
GSK and Merck KGaA partnered in a $4.2 billion cancer immunotherapy deal centered on M7824, with Merck receiving EUR 300 million upfront and potential…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK and Merck KGaA entered a global alliance to co-develop bintrafusp alfa (M7824), a bifunctional TGF-beta trap/anti-PD-L1 fusion protein. Deal terminated in 2021 after clinical failures.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Merck KGaA (this deal) | 2019 | $4.2B | 29 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2019 deals · GlaxoSmithKline plc deals · Oncology deals